With over 50 coronavirus vaccines in clinical trials and another 120 in pre-clinical development, who better to make sense of it all than The Wall Street Journal Heard On The Street Healthcare Columnist, Charley Grant. We talk about Pfizer and Moderna, and about the key efficacy and safety questions remaining for their trials, and also talk about the harsh reality that a coronavirus vaccine could still prove elusive. Investors should heed caution and tread carefully. Charley doesn't have all the answers, but his years of experience covering the space, lends to some very sound advice.

Want more?

Join the monthly HedgeD, With A Capital "D" webinar series by contacting us at [email protected]

Follow us on Twitter @HedgeD_Podcast

Visit us on the web at https://www.morgancreekcap.com/opportunistic-equity/